BPA ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
88慢性血栓塞栓性肺高血圧症10

88. 慢性血栓塞栓性肺高血圧症

臨床試験数 : 157 /  薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05140525
(ClinicalTrials.gov)		June 1, 202328/10/2021Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPHEffects of Combination Medical Therapy Followed by Balloon Pulmonary Angioplasty on Right Ventricular-PA Coupling and Hemodynamics in Chronic Thromboembolic Pulmonary HypertensionCTEPHDrug: Macitentan Tablets;Drug: Riociguat;Device: balloon pulmonary angioplastyDr Sudarshan RajagopalActelionNot yet recruiting18 YearsN/AAll15Phase 3United States
2ChiCTR2100052570
2021-08-012021-10-31A randomized controlled study of the effectiveness of percutaneous pulmonary thrombotic tissue aspiration in improving pulmonary blood flow grading in patients with chronic thromboembolic pulmonary hypertensionA randomized controlled study of the effectiveness of percutaneous pulmonary thrombotic tissue aspiration in improving pulmonary blood flow grading in patients with chronic thromboembolic pulmonary hypertension Chronic Thromboembolic Pulmonary HypertensionControl group:Traditional simple BPA procedure;Experimental group:Traditional simple BPA + thrombotic tissue removal;Fuwai Hospital, Chinese Academy of Medical SciencesNULLRecruiting1880BothControl group:20;Experimental group:20;China
3JPRN-jRCTs041200052
30/06/202122/10/2020THERAPY-HYBRID-BPA trialThe Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients after Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary Angioplasty. - Riociguat-CTEPH chronic thromboembolic pulmonary hypertension
CTEPH;D000081029		In this study, we will perform continuous verification by allocating the Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients whose hemodynamics were normalized after Balloon Pulmonary Angioplasty (BPA) to the the riociguat active group and placebo group for 16 weeks.Shimokawahara HirotoNULLRecruiting>= 18age old< 85age oldBoth72Phase 2Japan
4JPRN-jRCT1041200111
11/03/202111/03/2021Pharmacokinetic changes in Riociguat before and after catheterizationEffect of balloon pulmonary angioplasty on the pharmacokinetics of riociguat - BPA: Balloon Pulmonary Angiotherapy CTEPHRight heart catheterization on the day before BPA treatment and 3 months after BPA treatment, except at the time of blood sampling, which is usually performed in clinical practice. During hospitalization, 5 ml / dose of blood is taken 6 times (before and 30 minutes after taking the drug). , 1 hour after taking the drug, 2 hours after taking the drug, 3 hours after taking the drug, 5 hours after taking the drug).Tatsuguchi MarikoNULLRecruiting>= 20age old<= 80age oldBoth30N/AJapan
5ChiCTR2000032403
2021-01-012020-04-27Efficacy and safety of refined balloon pulmonary angioplasty combined with riociguat in the treatment of inoperable chronic thromboembolic pulmonary hypertension: a single center, open label, prospective, optimal, randomized, parallel controlled clinical study (PRACTICE study)Efficacy and safety of refined balloon pulmonary angioplasty combined with riociguat in the treatment of inoperable chronic thromboembolic pulmonary hypertension: a single center, open label, prospective, optimal, randomized, parallel controlled clinical study (PRACTICE study) chronic thromboembolic pulmonary hypertensionRiociguat Group:Riociguat;Riociguat+BPA Group:Riociguat and BPA;Shanghai Pulmonary HospitalNULLPending18BothRiociguat Group:30;Riociguat+BPA Group:30;China
6NCT04600492
(ClinicalTrials.gov)		October 16, 202019/10/2020THERAPY-HYBRID-BPA TrialThe Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in CTEPH Patients After Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary AngioplastyHypertension, PulmonaryDrug: Riociguat Oral TabletNational Hospital Organization Okayama Medical CenterBayer Yakuhin, Ltd.Recruiting18 Years85 YearsAll72Phase 2Japan
7ChiCTR2000034995
2019-06-012020-07-27Real world study on the changes of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension treated with percutaneous balloon pulmonary angioplasty versus targeted drug therapyReal world study on the changes of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension treated with percutaneous balloon pulmonary angioplasty versus targeted drug therapy pulmonary hypertensionBPA:BPA;Target Drug:Target Drug;BPA+Target Drug:BPA+Target Drug;The First Affiliated Hospital of Guangzhou Medical UniversityNULLRecruiting2080BothBPA:20;Target Drug:20;BPA+Target Drug:20;N/AChina
8JPRN-jRCTs031180239
14/04/201612/03/2019MR BPA studyMulticenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension - MR BPA study Chronic Thromboembolic Pulmonary HypertensionGroup A: BPA treatment
BPA is performed after allocation to this group (initial date of implementation will be the reference date). BPA will be completed within four months of the reference date.

Group B: Riociguat treatment
Riociguat treatment will be initiated after allocation to this group (the initial administration day will be the reference date). Riociguat will be initially administered three times per day at 1.0 mg per dose. Using systolic blood pressure (95 mmHg or higher) as a guide, the dose will be increased by 0.5 mg for each subject every two weeks with a thrice-daily administration of 2.5 mg/dose set as the maximum dosage. Dosage adjustment, including the maintenance dosage, is based on the judgment of the responsible investigators and investigators. Dosage adjustment will be completed within four months of the reference date.		Fukuda KeiichiKawakami TakashiComplete>= 20age old<= 80age oldBoth60N/AJapan
9JPRN-UMIN000019549
2016/04/0128/10/2015Multicenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertensionMulticenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension - Multicenter Randomized controlled trial based on Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension(MR BPA study) Chronic thromboembolic pulmonary hypertension (CTEPH)Group A: BPA treatment

Basically BPA treatment needs to be
finished within 4 months from the day of first BPA session

Group B: Riociguat treatment

First, starting with riociguat 3 times per day (1.0mg/time). Then increase the dose by 0.5mg every two weeks (with systolic blood pressure 95mmHg or higher).
The maximum dose is 2.5mg per dose (three times per day). Dosage is adjusted accordingly for each patient, and the adjustment is finished within 4 months from the day of starting riociguat.		Keio University School of MedicineNULLComplete: follow-up continuing20years-old80years-oldMale and Female60Not selectedJapan
10NCT02634203
(ClinicalTrials.gov)		January 19, 20168/12/2015Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary HypertensionRiociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary HypertensionChronic Thromboembolic Pulmonary HypertensionProcedure: Balloon Pulmonary Angioplasty (BPA);Drug: RiociguatAssistance Publique - Hôpitaux de ParisBayerCompleted18 Years80 YearsAll105N/AFrance

先頭へ